- Conditions
- Kidney Stones
- Interventions
- ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin
- Drug
- Lead sponsor
- University of British Columbia
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • San Diego, California • Baltimore, Maryland + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Tobacco Use Disorder
- Interventions
- Full Nicotine Cigarettes, Reduced Nicotine Cigarettes, Average Nicotine Expectancy, Very Low Nicotine Expectancy
- Drug · Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Seizures
- Interventions
- levetiracetam
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 1 Day to 30 Days
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- COVID-19, Long Haul
- Interventions
- Ritonavir-Boosted Nirmatrelvir (Paxlovid), Physiological Evaluation, Moderna COVID-19 Vaccine, Biopsychological, Behavioral (e.g., Psychotherapy, Lifestyle Counseling), Genetic (including gene transfer, stem cell and recombinant DNA), Multidisciplinary approach
- Drug · Diagnostic Test · Biological + 3 more
- Lead sponsor
- Well- Konnect Healthcare Services and Research Firm
- Network
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Food Hypersensitivity, Milk Hypersensitivity
- Interventions
- Baked Milk, Non-baked Milk
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 4 Years to 10 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
- Interventions
- Etirinotecan pegol (NKTR-102)
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Entinostat, Erlotinib
- Drug
- Lead sponsor
- Syndax Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 5
- States / cities
- San Diego, California • Miami, Florida • Chicago, Illinois + 2 more
- Conditions
- Primary Immunodeficiency Diseases (PID)
- Interventions
- Recombinant human hyaluronidase + immune globulin intravenous
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 3
- States / cities
- Centennial, Colorado • North Palm Beach, Florida • Dallas, Texas
- Conditions
- Graves Disease
- Interventions
- WP1302, WP1302 placebo, methimazole
- Drug · Combination Product
- Lead sponsor
- Worg Biotherapeutics Inc.
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 7
- States / cities
- Hunt, Arizona • Canoga Park, California • Littleton, Colorado + 4 more
- Conditions
- Risk Reduction
- Interventions
- Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation, Placebo
- Biological · Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Clostridiodies Difficile Infections
- Interventions
- MTC 01, Fecal Microbiota Transplantation (FMT)
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Rett Syndrome
- Interventions
- NGN-401
- Genetic
- Lead sponsor
- Neurogene Inc.
- Industry
- Eligibility
- 3 Years and older · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Oakland, California • Aurora, Colorado + 10 more
- Conditions
- Exudative Age Related Macular Degeneration
- Interventions
- Ranibizumab, Photodynamic laser treatment (PDT), Triamcinolone Acetonide, verteporfin
- Drug · Device
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 50 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Meconium Aspiration
- Interventions
- Lucinactant, Standard Care
- Drug · Other
- Lead sponsor
- Windtree Therapeutics
- Industry
- Eligibility
- Up to 48 Hours
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 1
- States / cities
- Warrington, Pennsylvania
- Conditions
- Uterine Atony, Uterine Atony With Hemorrhage, Cesarean Section Complications
- Interventions
- Calcium Chloride, Placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Influenza
- Interventions
- 3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A, 3.75 µg H5N8 antigen plus half dose AS03A, 7.5 µg H5N8 antigen plus half dose AS03A, 15 µg H5N8 antigen plus half dose AS03A, 3.75 µg H5N8 antigen plus MF59, 7.5 µg H5N8 antigen plus MF59, 15 µg H5N8 antigen plus MF59, 3.75 µg H5N1 antigen plus full dose AS03A, 7.5 µg H5N1 antigen plus full dose AS03A, 15 µg H5N1 antigen plus full dose AS03A, 3.75 µg H5N1 antigen plus MF59, 7.5 µg H5N1 antigen plus MF59, 15 µg H5N1 antigen plus MF59
- Biological
- Lead sponsor
- Biomedical Advanced Research and Development Authority
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 1,380 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 20
- States / cities
- Atlanta, Georgia • Savannah, Georgia • Oak Lawn, Illinois + 17 more
- Conditions
- COVID-19
- Interventions
- Shionogi Protease Inhibitor (S-217622), placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Fresno, California + 75 more
- Conditions
- Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia, Diamond-Blackfan Anemia, Shwachman-Diamond Syndrome
- Interventions
- Busulfan, Fludarabine, ATG, TLI, Busulfan, Cyclophosphamide, ATG, GCSF, Campath, Fludarabine, Cyclophosphamide, Total Body Irradiation, Stem cell infusion
- Drug · Radiation · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 50 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2020
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Alcohol Use Disorder
- Interventions
- Cannabidiol, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Leukemia, Myelodysplastic Syndrome
- Interventions
- ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Sclerosis
- Interventions
- NLY01, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • New York, New York
- Conditions
- Crohn's Disease
- Interventions
- EBFAHF-2, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Teclistamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 587 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Duarte, California • Stanford, California + 14 more
- Conditions
- Prostate Cancer, Localized Prostate Carcinoma
- Interventions
- Leuprolide, Degarelix, Relugolix, Triptorelin, Bicalutamide, 18-F Flotufolastat PSMA PET, Radical prostatectomy
- Drug · Diagnostic Test · Procedure
- Lead sponsor
- Baptist Health South Florida
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Miami, Florida